Rumors that Amazon is looking to parachute into the drug field are getting louder. Amazon is already in talks with pharmacy benefits managers, an analyst reports, and that poses a larger threat to the pharma industry than some might realize.
The retail giant has stayed quiet about its pharma ambitions, but a Goldman Sachs analyst last month outlined some potential pharmaceutical strategies the company might use. Now, Leerink Partners has published a report saying the category-killer is in talks with mid-size PBMs “in an effort to get into various contract arrangements,” according to multiple media reports.
A potential entrance into the drug business could take 18 to 24 months, according to Leerink, but Amazon could be a “bigger threat” to the pharmaceutical status quo than many appreciate.
There’s plenty of reason Amazon might want to get into the drug supply chain. According to the Goldman Sachs analysis, the field is worth $125 billion each year, or 30% of U.S. net pharma spending. To start, the company might offer a strong user experience and a top-notch logistics network, later looking to change transparency dynamics on pricing, according to the Goldman analysts.
Goldman Sachs analysts published their 30-page report in August as a way to spark conversation among investors about Amazon’s options in pharmaceuticals. They said the company might partner with a PBM as a “path of least resistance.” Other routes into pharma for Amazon would be as an online pharmacy, a retail plus online pharmacy, an integrated PBM or a distribution player to pharmacies, according to Goldman.
But the PBM space is dominated by a few major players, and any potential disruptor would need to build up scale to make meaningful change. Other complexities such as pricing could pose challenges for Amazon in the field.
Talk of Amazon’s entry into the drug supply chain comes as tensions have been somewhat strained between pharmaceutical companies and drug middlemen, amid ongoing public angst over drug prices. Drug companies have been blaming growing PBM rebates for a rise in prices, while PBMs say their tough negotiations save the health systems billions in costs.
By Eric Sagonowsky
Source: Fierce Pharma
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
